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Hyperphosphatemic familial tumoral calcinosis (HFTC)/hyperostosis-hyperphosphatemia syndrome (HHS) is an autosomal
recessive disorder of ectopic calcification due to deficiency of or resistance to intact fibroblast growth factor 23 (iFGF23).
Inactivating mutations in FGF23, N-acetylgalactosaminyltransferase 3 (GALNT3), or KLOTHO (KL) have been reported as
causing HFTC/HHS. We present what we believe is the first identified case of autoimmune hyperphosphatemic tumoral
calcinosis in an 8-year-old boy. In addition to the classical clinical and biochemical features of hyperphosphatemic tumoral
calcinosis, the patient exhibited markedly elevated intact and C-terminal FGF23 levels, suggestive of FGF23 resistance.
However, no mutations in FGF23, KL, or FGF receptor 1 (FGFR1) were identified. He subsequently developed type 1 diabetes
mellitus, which raised the possibility of an autoimmune cause for hyperphosphatemic tumoral calcinosis. Luciferase
immunoprecipitation systems revealed markedly elevated FGF23 autoantibodies without detectable FGFR1 or Klotho
autoantibodies. Using an in vitro FGF23 functional assay, we found that the FGF23 autoantibodies in the patient’s plasma
blocked downstream signaling via the MAPK/ERK signaling pathway in a dose-dependent manner. Thus, this report describes
the first case, to our knowledge, of autoimmune hyperphosphatemic tumoral calcinosis with pathogenic autoantibodies
targeting FGF23. Identification of this pathophysiology extends the etiologic spectrum of hyperphosphatemic tumoral
calcinosis and suggests that immunomodulatory therapy may be an effective treatment.

Introduction

Fibroblast growth fact 23 (FGF23) is a phosphate- and 1,25(OH)2 vitamin D–regulating (1,25D-regulating) hormone produced by osteoblasts and osteocytes (1). FGF23 acts via FGF receptor 1 (FGFR1)
coupled with the coreceptor αKlotho to reduce expression of sodium
phosphate cotransporters (NaPi-2a and -2c) and renal 25-hydroxy
vitamin D 1-α-hydroxylase (2). FGF23 lowers serum phosphorus and
1,25D levels by its actions on the kidney to reduce renal tubular reabsorption of phosphate (TRP) and 1,25D production. Excess FGF23
has been implicated in a number of hypophosphatemic disorders,
such as tumor-induced osteomalacia (3), X-linked hypophosphatemia (4), and autosomal dominant hypophosphatemic rickets (5).
Hyperphosphatemic familial tumoral calcinosis (HFTC)/
hyperostosis-hyperphosphatemia syndrome (HHS) (OMIM

Conflict of interest: The NIDCR has received financial support from Shire, Novartis,
and BridgeBio for research using pharmaceutical agents not discussed in this work. MSR
became an employee of Ultragenyx Pharmaceutical in September 2017, after work on
this project was completed. Indiana University has licensed FGF23 to Kyowa Hakko Kirin
Co., and MJE receives royalty income through this license. MJE serves as a consultant to
Ultragenyx Pharmaceutical and receives research support from Horizon Pharma for an
unrelated trial.
License: Copyright 2018, American Society for Clinical Investigation.
Submitted: May 7, 2018; Accepted: September 11, 2018.
Reference information: J Clin Invest. 2018;128(12):5368–5373.
https://doi.org/10.1172/JCI122004.

5368

jci.org   Volume 128   Number 12   December 2018

211900) is a disorder of FGF23 deficiency or resistance. Affected
individuals develop ectopic calcifications called tumoral calcinosis and/or diaphyseal hyperostosis, which manifests clinically in
the long bones as diaphyseal pain and swelling (6). Characteristic
dental findings of HFTC/HHS include shortened roots with dilacerations, thistle-shaped dental pulps, pulp chamber and root canal
obliteration, and pulp stones (7). In addition, some patients experience systemic inflammation.
HFTC/HHS is an autosomal recessive disease, and to date,
causal mutations in 3 genes have been identified: FGF23 (12p13.3)
(8), UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase
3 (GALNT3) (2q24-q31) (9), and Klotho (KL) (13q12) (10). Mutations in FGF23 and GALNT3 result in premature cleavage of biologically active intact FGF23 (iFGF23) into inactive fragments,
while mutations in KL interrupt FGF23 signaling, causing FGF23
resistance. Lack of iFGF23 results in hyperphosphatemia, due
to increased TRP and elevated or inappropriately normal 1,25D
production, which promotes gastrointestinal absorption of phosphorus and calcium. The net effect is an increase in the calcium ×
phosphate product, leading to tumoral calcinosis.
Here, we present what we believe is the first case of autoimmune hyperphosphatemic tumoral calcinosis due to pathogenic
FGF23 autoantibodies. Autoantibodies directed against extracellular targets, such as receptors (e.g., nicotinic acetylcholine
receptor autoantibodies in myasthenia gravis) or secreted mole-
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ic cause, we questioned whether
an interfering antibody led to
falsely elevated iFGF23 and
CFGF23 levels. Therefore, we
cules (e.g., granulocyte-macrophage–stimulating factor autoantiperformed serial dilutions of the patient’s plasma (1:1, 1:10, 1:20,
bodies in pulmonary alveolar proteinosis), have been previously
1:50, 1:100, 1:500, 1:1000) and measured iFGF23 and CFGF23 via
described as causing human disease (11). In this case, the patient
second-generation ELISA kits (Immutopics). For both iFGF23 and
exhibited classic features of HFTC/HHS: tumoral calcinosis with
CFGF23, levels decreased with serial dilution as expected, except
hyperphosphatemia in the setting of normal renal function and
for the 1:500 and 1:1000 dilutions of iFGF23, which were below
increased TRP. iFGF23 levels were high, suggesting FGF23 resisthe lower limit of detection of the assay (Supplemental Table 1).
tance. However, a causative genetic mutation was not identified.
The ability to detect dilutions of iFGF23 and CFGF23 via ELISA
After the patient subsequently developed type 1 diabetes mellitus
ruled out the presence of an interfering antibody resulting in the
(T1DM), an autoimmune disease, luciferase immunoprecipitation
elevated iFGF23 and CFGF23 levels.
systems (LIPS) (12) were used to detect potential autoantibodies
Twenty months after initial symptom onset, the patient reportagainst proteins in the FGF23-signaling receptor complex. An in
ed a 2-week history of polyuria, polydipsia, and nocturia, with
vitro FGF23 functional assay was performed to assess the effect of
no change in appetite or weight. He denied dysuria, hematuria,
FGF23 autoantibodies on FGF23 signal transduction.
enuresis, or fever. Laboratory evaluation revealed blood phosphorus of 5.6 mg/dl (normal for age, 3–5.7), 1,25D of 59 pg/ml (normal, 24–86), and TRP of 93% (normal, 85%–95% in the setting of
Results and Discussion
normal blood phosphorus). iFGF23 and CFGF23 levels remained
This White boy presented at 6 years, 3 months, with pain, swellmarkedly elevated at 6900 pg/ml (normal, <52) and 22,400 RU/
ing, and development of a firm lesion on the lateral right hip. MRI
ml (normal for age ≤230), respectively. In addition, the subject was
of the lesion revealed a calcified mass in the right gluteus maxihyperglycemic (fasting blood glucose, 433 mg/dl; normal, < 120)
mus extending into the subcutaneous soft tissue. A biopsy of the
and insulinopenic (4.1 mcU/ml; normal fasting, 2.6–24.9) with a
lesion showed tumoral calcinosis. Subsequent laboratory evallow C-peptide (0.8 ng/ml; normal, 1.1–1.5). Hemoglobin A1c was
uation revealed hyperphosphatemia (7.2 mg/dl; normal for age,
elevated at 10.7% (estimated average glucose, 260 mg/dl) (Table
3.2–6.3) with normal blood calcium and renal function, consistent
1). The subject had positive islet antigen-2 (IA-2) and antiinsulin
with the diagnosis of HFTC/HHS. iFGF23 and C-terminal FGF23
antibodies and negative glutamic acid decarboxylase (GAD65)
(CFGF23) levels were markedly elevated, at 13,000 pg/ml (norantibodies. Of note, he had a normal fasting blood glucose of 81
mal, <52) and 33,000 RU/ml (normal for age, ≤230) (Table 1),
mg/dl 3 months prior. These results were consistent with newrespectively, consistent with FGF23 resistance. The patient was
onset T1DM. The patient was admitted for initiation of insulin
started on the phosphate binder sevelamer and a low-phosphate
therapy and diabetes education.
diet. Sequencing of FGF23, KL, and FGFR1 genes and wholeGiven the lack of an identifiable genetic cause for hyperphosexome sequencing did not identify gene mutations or genetic variphatemic tumoral calcinosis and the new diagnosis of T1DM, we
ants, including mutations and/or variants in GALNT3, that could
hypothesized that the tumoral calcinosis could be autoimmune
explain the clinical calcinosis/phosphate phenotype.

Table 1. Biochemical results in patient with autoimmune tumoral calcinosis
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Figure 1. Clinical presentation and radiographs of patient with tumoral
calcinosis. (A) Tumoral calcinosis (arrows) of the lateral right hip at initial
presentation to the NIH at 7 years, 3 months old. (B) Radiograph of the
lesion revealed a soft tissue mass with amorphous calcifications around
the right greater trochanter consistent with tumoral calcinosis. Repeat
evaluation 9 months after initial presentation while on phosphate-lowering medications (sevelamer and acetazolamide) and a low-phosphate diet
showed decrease in the size of the tumoral calcinosis (arrows) on physical
exam (C) and repeat radiograph (D).

in nature. Based on previously described LIPS tests for IA-2 (13)
and GAD65 (14) autoantibodies, our patient demonstrated seropositive autoantibodies against IA-2 (Figure 2A) and seronegative autoantibodies to GAD65 (Figure 2B), consistent with results
obtained at diagnosis of T1DM. In order to test the hypothesis that
autoantibodies might be directed against extracellular components of the FGF23-signaling pathway, light-emitting luciferase
fusion proteins for FGF23, FGFR1, and Klotho were generated for
LIPS autoantibody profiling (12). Remarkably, the patient showed
very high levels of autoantibodies against the FGF23-Gaussia
luciferase fusion protein. These were 60-fold higher than those
of other patients with HFTC due to mutations in GALNT3 (Figure
2C). Moreover, patients with a variety of other autoimmune diseases including Sjögren syndrome, systemic lupus erythematosus,
vasculitis, and T1DM, were all seronegative for FGF23 autoantibodies (Figure 2C). No significant detectable immunoreactivity
was found against FGFR1 (Figure 2D) and Klotho (Figure 2E), as
the autoantibody levels in the patient were comparable to those
of other patients with HFTC and healthy controls. These findings
demonstrate the patient had elevated levels of autoantibodies that
were selectively against FGF23, but not against the corresponding
receptor proteins for this ligand. Because FGF23 autoantibody
titers were only measured at 2 time points, a potential correlation
between autoantibody levels and blood phosphorus, FGF23, and
1,25D could not be evaluated.
While we have not mapped the regions of FGF23 reacting
with the patient’s autoantibodies, it is likely that the patient harbors a complex mixture of autoantibodies that target both linear
and conformational epitopes of FGF23 and block the action of
FGF23 on its receptor. Interestingly, the patient’s autoantibodies did not interfere with the iFGF23 or CFGF23 ELISA assays.
This is likely explained by the fact that the antibodies used in the
5370

jci.org   Volume 128   Number 12   December 2018

ELISAs are generated against relatively small, defined polypeptides derived from the 2 ends of the FGF23 protein and would not
be influenced by the existing patient’s autoantibodies. Studies
with other pathogenic autoantibodies, including pulmonary alveolar proteinosis and membranous nephropathy, have also used similar antibody-based methods to establish that the protein levels of
the granulocyte-macrophage CSF (GM-CSF) (15) and anti-phospholipase A2 receptor (PLA2R) (16), respectively, are unchanged
or increased in these autoimmune diseases. Finally, our concordant findings from 2 different commercial ELISA assays showing
comparable results with elevated FGF23 protein levels potentially
support the validity of this approach.
Based on the elevated FGF23 autoantibodies found in the
patient, we tested the effect of FGF23 autoantibodies on FGF23
signaling in an in vitro functional assay. Human embryonic kidney cells (HEK293) stably transfected with the full-length transmembrane form of mouse Klotho (17) were treated with vehicle
(PBS), recombinant human FGF23 R176Q, or basic FGF (bFGF) in
the presence of either 2% plasma from our patient or 2% human
control plasma. Recombinant FGF23 increased early growth
response 1 (EGR1) mRNA expression in a dose-dependent manner, whereas the patient’s plasma blocked the FGF23-dependent
increase in EGR1 mRNA expression. The inhibitory effect of the
patient’s plasma on EGR1 mRNA expression was overcome with
the addition of 100 ng/ml FGF23 (Figure 3A). Control plasma had
no effect on EGR1 mRNA expression at any FGF23 concentration
(Figure 3B). Recombinant bFGF increased EGR1 mRNA expression independently of the patient’s plasma (Figure 3C), indicating
that autoantibodies present in our patient’s plasma are specific in
blocking the action of FGF23.
FGF23 binding to the FGFR1-Klotho receptor complex
leads to ERK1/2 phosphorylation. We analyzed FGF23-depen-
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Figure 2. LIPS detection of autoantibodies. LIPS evaluation revealed the patient (red star) had seropositive autoantibodies against IA-2 (A), consistent
with the diagnosis of T1DM, and seronegative autoantibodies to GAD65 (B). The patient showed very elevated levels of autoantibodies against FGF23 that
were 60-fold higher than those of other patients with HFTC/HHS. The patient also had substantially higher levels of FGF23 autoantibodies compared with
healthy controls and other patients with a variety of autoimmune diseases. SS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; vasc, vasculitis.
(C). The patient (red star) had levels of autoantibodies to FGFR1 (D) and Klotho (E) that were similar to those of other patients with HFTC and healthy
controls. Dotted lines show mean light units (LU) value plus 3 SDs of the serum samples from healthy controls (14). Neg, negative.

dent phosphorylation of ERK1/2 in HEK293-Klotho cells in the
presence or absence of patient or control plasma. Recombinant
FGF23 significantly increased ERK1/2 phosphorylation, which
was blocked by the patient’s plasma (Figure 3, D and G), suggesting that the patient’s plasma blocks FGF23 binding to its receptor.
Control plasma did not interfere with ERK1/2 phosphorylation
(Figure 3, E and H). Furthermore, bFGF increased ERK1/2 phosphorylation, but the patient’s plasma had no inhibitory effect on
ERK1/2 phosphorylation upon bFGF treatment (Figure 3, F and I).
Changes in EGR1 protein levels were not assessed in the in vitro
assay, given that the patient’s plasma with FGF23 was shown
to block both EGR1 expression and ERK1/2 phosphorylation,
which is not seen with control plasma/FGF23 or the patient’s
plasma/bFGF. This is comparable to what has been shown in the
Hyp mouse, which, when treated with an ERK1/2 inhibitor, had
decreased FGF23 signaling and increased serum phosphorus,
1,25D, and skeletal mineralization (18, 19).
Given the onset of 2 autoimmune diseases within 2 years, we
examined the patient’s autoimmune and immunological characteristics. Lymphocyte immunophenotyping using flow cytometry
was performed. The patient had an overall normal cell profile
with normal plasmablasts and total B cells with typical representation of immature, transitional, and memory B cell subsets.
He had low levels of the autoreactive CD21loCD38lo B cell subset
(20), which is enriched in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) (21),

common variable immunodeficiency-associated autoimmune
cytopenias (22), and cytotoxic T lymphocyte–associated protein
4 (CTLA4) haploinsufficiency-associated immune dysregulation
(23). Evaluation of T and B cell clonality was performed via PCR
amplified for detection of immunoglobulin (IgH and IgK loci) and
T cell receptor gene rearrangements. No significant T or B cell
populations were identified. The subject was screened for autoantibodies associated with other autoimmune diseases and did
not demonstrate autoantibodies to thyroglobulin, thyroid peroxidase, tissue transglutaminase, intrinsic factor, parietal cells, and
21-hydroxylase. He had normal immunoglobulin (IgG, IgA, and
IgM) levels. Although the exact mechanism involved in the generation of anti-FGF23 autoantibodies in this subject is unknown, we
speculate that autoreactive B cells not identified in the immune
cell evaluation and/or epitope spreading in the context of T1DM
might be responsible. Given the lack of an identifiable target for
treatment, immunomodulatory medications were not recommended for this patient.
Here, we describe what we believe is the first case of pathogenic autoantibodies that target FGF23, causing hyperphosphatemic
tumoral calcinosis. This observation is supported by identification
of elevated levels of FGF23 autoantibodies, which, in vitro, block
FGF23 action at the level of the FGFR1-Klotho receptor complex.
We speculate that the FGF23 autoantibodies likely sequester
FGF23 and prevent it from interacting with its receptor to promote
normal signal transduction. The present data depict a pathophysjci.org   Volume 128   Number 12   December 2018
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Figure 3. The effect of patient plasma on FGF23 signaling in HEK293-Klotho cells. Relative EGR1 mRNA expression compared with 18S rRNA in HEK293Klotho cells treated for 2 hours with either recombinant human FGF23 (vehicle, 25, 50, or 100 ng/ml) (A and B) or recombinant human bFGF (vehicle or
10 ng/ml) (C) and ±2% patient plasma (A and C) or ±2% control plasma (B). n = 3. Single independent experiments were normalized to their untreated
controls. Fold change of phosphorylated ERK1/2 (p-ERK1/2) protein abundance compared with ERK1/2 in HEK293-Klotho cells treated for 15 minutes with
either vehicle, recombinant human FGF23 (25 ng/ml) (D, E, G, H), or recombinant human bFGF (10 ng/ml) (F and I) and ±2% patient plasma (D, F, G, I) or
±2% control plasma (E and H). n = 3–6. Single independent experiments were normalized to vehicle control. Representative blots of single experiments
show decreased p-ERK1/2 protein abundance with recombinant FGF23 (25 ng/ml) compared with vehicle-treated cells in the presence of patient’s plasma
(G). Addition of control plasma in the presence of FGF23 resulted in no change in p-ERK1/2 protein abundance (H). There was no change in p-ERK1/2 protein abundance with bFGF (10 ng/ml) in the presence of patient’s plasma (I). Data are presented as mean + SD, and 2-way ANOVA followed by Tukey’s test
for multiple comparisons was used for statistical analysis. *P < 0.05.

iology for hyperphosphatemic tumoral calcinosis and suggest a
potential role for immunomodulatory therapy in the treatment of
this disease if an immunological target can be identified.

Methods

Further information is provided in Supplemental Methods.
Statistics. The statistical analyses were performed using 2-way
ANOVA, followed by Tukey’s test for multiple comparisons (GraphPad Prism, version 7.02). Data are provided as mean + SD. A P value of
less than 0.05 was considered statistically significant.
Study approval. This study was approved by the Institutional
Review Board of the NIDCR (NIH). The parents of the subject provided written consent to the study protocol, and the subject provided
written assent.
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